This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CAPT. D. JOSEPH DEMIS, MC; CRAWFORD S. BROWN, M.D.

Arch Dermatol. 1962;85(2):276-278.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Prior to the development and introduction of griseofulvin, ringworm infections of the nails were almost completely resistant to therapy.¹ Griseofulvin has proven an effective agent in the therapy of onychomycosis; however, when it is administered orally, infections of the fingernails require 6 to 9 months of therapy with the drug and toenail infections require 12 to 18 months or longer. This form of treatment has additional disadvantages, for while the cure rate approximates 90% for fingernails, the cure rate for toenails is probably closer to 10%. Moreover, the prolonged oral dosage is expensive, and, as in any systemic medication, the problems of intolerance, sensitization, untoward reactions, and potential toxicity are present.

This is a preliminary report of our experience with the topical use of griseofulvin for onychomycosis after surgical avulsion of the nail. This technique was adopted for trial when intolerance to griseofulvin developed after oral administration over prolonged periods. . . . [Full Text PDF of this Article]

Author Affiliations
USA; WASHINGTON, D.C.

From the Department of Dermatology, Walter Reed Army Institute of Research, Washington, D.C. (Capt. Demis), and the Department of Dermatology, The George Washington University Medical School, Washington, D.C. (Dr. Brown).

Footnotes
Submitted for publication Aug. 30, 1961.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?